BRISA | Regional Base of Health Technology Assessment Reports of the Americas Regional Base of Health Technology Assessment Reports of the Americas
Home > BRISA > Search result
COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.


Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 4

Informe diário de evidências COVID-19: busca realizada em 7 de julho de 2020

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde.
O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referente ao di...
Coronavirus Infections/drug therapy, Pneumonia, Viral/drug therapy, Betacoronavirus/drug effects, Hydroxychloroquine/therapeutic use, Chloroquine/therapeutic use, Lopinavir/therapeutic use, Ritonavir/therapeutic use, Azithromycin/therapeutic use, Amoxicillin/therapeutic use, Ceftriaxone/therapeutic use, Steroids/therapeutic use, Adrenal Cortex Hormones/therapeutic use, Leflunomide/therapeutic use, Methotrexate/therapeutic use, Mycophenolic Acid/therapeutic use, Oseltamivir/therapeutic use, Warfarin/therapeutic use, Ivermectin/therapeutic use, Vitamin D/therapeutic use, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Infliximab/therapeutic use, Technology Assessment, Biomedical
Fulltext

COVID-19 et impact de la substitution du CoumadinMD sur les tests de laboratoire

Institut National d’Excellence en Santé et en Services Sociaux.
CONTEXTE: Le présent document ainsi que les constats qu’il énonce ont été rédigés en réponse à une interpellation du ministère de la Santé et des Services sociaux. L’annonce d’un arrêt de commercialisation de toutes les teneurs de ce produit utilisé par quelque 100000 patients au Québe...
Coronavirus Infections/drug therapy, Warfarin/therapeutic use, Drug Substitution, Technology Assessment, Biomedical, Health Evaluation
Fulltext

Análisis de impacto presupuestal de dabigatran, rivaroxaban y apixaban comparado con warfarina para prevención de fenómeno tromboembólico e isquémico en pacientes con fibrilación auricular no valvular en Colombia

Arce Correa, Juan Felipe; Peña, Esperanza; Rodriguez Pinzón, Edisson Ernesto.
Tecnologías evaluadas: Dabigatran, rivaroxaban y apixaban, comparado con warfarina. Población: Pacientes adultos con fibrilación auricular no valvular en Colombia. Perspectiva: Tercer pagador - Sistema General de Seguridad Social en Salud. Horizonte temporal: El horizonte temporal de esta AIP en el ca...
Thromboembolism/prevention & control, Ischemia/prevention & control, Atrial Fibrillation/drug therapy, Dabigatran/therapeutic use, Rivaroxaban/therapeutic use, Factor Xa Inhibitors/therapeutic use, Warfarin/therapeutic use, Costs and Cost Analysis/methods, Biomedical Technology, Colombia, Reproducibility of Results, Health Evaluation/economics
Fulltext

CoaguChek no monitoramento do INR em pacientes recebendo tratamento com varfarina

Brasil. Ministério da Saúde. Comissão Nacional de Incorporação de Tecnologias no SUS.
A principal indicação apontada pela demandante para o uso do CoaguChek XS é em especial aos pacientes com Fibrilação Atrial (FA) crônica, cuja terapia anti-trombótica se estabeleceu como parte importante do tratamento. Pacientes de alto risco para fenômenos tromboembólicos, frequentemente, tambÃ...
Anticoagulants/therapeutic use, Drug Monitoring, Blood Coagulation/drug effects, Prothrombin Time/methods, Warfarin/therapeutic use, Warfarin/28898, Cost-Benefit Analysis, Technology Assessment, Biomedical, Brazil, Unified Health System
Fulltext